| 產(chǎn)品描述： | GSK2334470 is a highly specific and potent inhibitor of PDK1 with an IC50 of 10 nM. |
| 靶點(diǎn)： |
IC50: 10 nM(PDK1);PDK |
| 體內(nèi)研究： |
The efficacy of the PDK1 inhibitor (PDKi) GSK2334470 is tested in newborn BrafV600E::Pten?/?mice subjected to systemic administration of 4-HT. Twice weekly administration of PDK1 results in marked inhibition of pigmented lesions and concomitant melanomagenesis, as well as significant inhibition of lung metastases, seen by H&E staining-based quantification (~80%), and lymph node metastases as by S100 immunostaining, similar to the phenotype seen upon genetic ablation of Pdk1 |
| 參考文獻(xiàn)： |
1. Najafov A, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J.?2011 Jan 15;433(2):357-69. 2. Qi L, et al. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int.?2015 Sep 29;15:91. 3. Scortegagna M, et al. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9. |
| 溶解性： |
DMSO : ≥ 50 mg/mL (108.09 mM) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.162 ml |
10.809 ml |
21.617 ml |
| 5 mM |
0.432 ml |
2.162 ml |
4.323 ml |
| 10 mM |
0.216 ml |
1.081 ml |
2.162 ml |
| 50 mM |
0.043 ml |
0.216 ml |
0.432 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京